ARTICLES| VOLUME 4, ISSUE 3, E179-E191, MARCH 2023 Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis Bradley J Langford, Miranda So, Marina Simeonova, et al Lancet Microbe Published:January 31, 2023 DOI:https://doi.org/10.1016/S2666-5247(22)00355-X Summary Background Frequent use of antibiotics in patients with COVID-19 threatens to exacerbate antimicrobial resistance. We aimed to establish the pr...

ARTICLES| VOLUME 4, ISSUE 3, E159-E170, MARCH 2023 Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study Jinnethe Reyes, Lauren Komarow, Liang Chen, et al. Lancet Microbe 2023; 4: E159-E170 Published: February 09, 2023 DOI:https://doi.org/10.1016/S2666-5247(22)00329-9 Summary Background Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a gl...

ARTICLES|ONLINE FIRST Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study Neil R Aggarwal, Kyle C Molina, Laurel E Beaty, et al. Lancet Infect Dis Published: February 10, 2023 DOI:https://doi.org/10.1016/S1473-3099(23)00011-7 Summary Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2, and ri...

ARTICLES|ONLINE FIRST Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study Martin Hoenigl, Jon Salmanton-García, Matthias Egger, et al Lancet Infect Dis Published: February 15, 2023 DOI:https://doi.org/10.1016/S1473-3099(22)00872-6 Summary Background The European Confederation of Medical Mycology (ECMM) collected data on epidemiology, risk factors, ...

CORRESPONDENCE|ONLINE FIRST Infection rate in Guangzhou after easing the zero-COVID policy: seroprevalence results to ORF8 antigen Junyuan Huang, Shi Zhao, Ka Chun Chong, et al. Lancet Infect Dis Published: February 17, 2023 DOI:https://doi.org/10.1016/S1473-3099(23)00112-3 On Dec 7, 2022, the Chinese government announced ten measures indicating the end of the zero-COVID policy, which was in effect for more than 2 years.1 Most of the stringent preventive me...

於服用口服抗病毒藥的新冠病毒住院患者中，病毒量反彈的風險因素及相關臨床結果: 一項 回顧性隊列研究 ARTICLES|ONLINE FIRST Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study Carlos K H Wong, Kristy T K Lau, Ivan C H Au, et al. Lancet Infect Dis Published: February 13, 2023 DOI:https://doi.org/10.1016/S1473-3099(22)00873-8 Summary Background Viral rebound after ...

ORIGINAL ARTICLE Hydrocortisone in Severe Community-Acquired Pneumonia Pierre-François Dequin, Ferhat Meziani, Jean-Pierre Quenot, et al N Engl J Med March 21, 2023DOI: 10.1056/NEJMoa2215145 Abstract BACKGROUND Whether the antiinflammatory and immunomodulatory effects of glucocorticoids may decrease mortality among patients with severe community-acquired pneumonia is unclear. METHODS In this phase 3, multicenter, double-blind, randomized, controlle...

CCBYNC Open accessResearch Effect of a multifaceted antibiotic stewardship intervention to improve antibiotic prescribing for suspected urinary tract infections in frail older adults (ImpresU): pragmatic cluster randomised controlled trial in four European countries Esther A R Hartman, Alma C van de Pol, Silje Rebekka Heltveit-Olsen, et al BMJ 2023; 380 doi: https://doi.org/10.1136/bmj-2022-072319 (Published 22 February 2023)Cite this as: BMJ 2023;380:e07231...

Original Investigation  February 20, 2023 Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial Susanna Naggie, David R. Boulware, Christopher J. Lindsell, et al JAMA. Published online February 20, 2023. doi:10.1001/jama.2023.1650 Key Points Question  Does ivermectin, with a maximum targeted dose of 600 μg/kg daily for 6 days, compared with p...

Original Investigation  February 21, 2023 History of Low Hourly Wage and All-Cause Mortality Among Middle-aged Workers Katrina L. Kezios, Peiyi Lu, Sebastian Calonico, et al JAMA. 2023;329(7):561-573. doi:10.1001/jama.2023.0367 Key Points Question  Is a history of sustained low-wage earning during peak midlife earning years associated with elevated mortality risk and excess mortality? Findings  In a longitudinal stud...